早期乳腺癌的进展:是花时间还是承担风险?
本文讨论发达国家早期乳腺癌预后改善后,随机对照试验因事件率降低而需更大规模、更长时间才能获得可靠结果;作者指出依赖观察性数据判定疗效及使用替代标志物(新辅助化疗后病理完全缓解)加速进展存在缺陷,并提出简化随机对照试验实施的建议。
要点
- 早期乳腺癌辅助治疗获益已获大型随机对照试验和荟萃分析证实。
- 事件率降低使随机对照试验需更大规模、更长时间才能得出可靠结果。
- 作者指出依赖观察性数据判定疗效及使用病理完全缓解作为替代标志物存在缺陷。
核心结论
- 作者强调依赖观察性数据判定疗效和使用病理完全缓解作为替代标志物存在缺陷,并建议简化随机对照试验的实施。
研究设计与样本
- 本文为讨论早期乳腺癌随机对照试验方法学问题的文章,未报告系统检索范围或样本量。
主要发现
- 发达国家早期乳腺癌患者预后近几十年来大幅改善,辅助治疗贡献了该改善。
- 事件率降低使随机对照试验需更大规模、更长时间才能提供可靠结果。
- 为维持进展速度并避免大型随机对照试验的复杂性、成本和时间,依赖观察性数据判定疗效及使用替代标志物加速进展的趋势增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes for patients diagnosed with early breast cancer in developed countries have improved substantially over recent decades. Adjuvant therapies have contributed to this improvement and their benefits have been confirmed in large randomised controlled trials (RCTs) and meta-analyses. Lower event rates, whilst welcome, have created problems for RCTs, that need to be larger and often take longer to provide a reliable result. In an effort to maintain the rate of progress and to obviate the complexity, cost and time required to conduct large RCTs, there has been an increased tendency to rely on observational data to determine a treatment effect and also to accelerate progress by the use of a surrogate marker (pathological complete remission after neoadjuvant chemotherapy). We highlight the pitfalls in these approaches and suggest some simplifications in the conduct of RCTs.
引用
- Mannu GS, Dodwell D. Making progress in early breast cancer: Taking time or accepting risk? Eur J Cancer. 2017. PMID: 28411447. doi:10.1016/j.ejca.2017.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。